Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.370
-0.530-2.96%
Volume:4.98M
Turnover:86.67M
Market Cap:46.19B
PE:11.72
High:17.800
Open:17.800
Low:17.180
Close:17.900
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.02
T/O Rate:0.92%
Dividend:0.46
Dividend Rate:2.62%
EPS(LYR):1.482
ROE:7.04%
ROA:1.53%
PB:0.81
PE(LYR):11.72
PS:0.94

Loading ...

FOSUN PHARMA’s 2025 ESG Report Highlights: AA MSCI Rating, RMB 5.91 Billion R&D Spend, and Strong Green, Social Commitments

Bulletin Express
·
Apr 21

Fosun Pharma Releases 2025 ESG and Sustainability Report

Bulletin Express
·
Apr 21

复星医药2025年报:净利润同比增至33.71亿元,业务与治理结构持续优化

Bulletin Express
·
Apr 21

FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements

Bulletin Express
·
Apr 21

BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPA

Reuters
·
Apr 14

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

MT Newswires Live
·
Apr 14

Fosun Pharma receives NMPA green light for Phase I/II trials of dual-target CAR-T therapy FKC289

Bulletin Express
·
Apr 14

Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection

THOMSON REUTERS
·
Apr 14

FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News
·
Apr 14

Hong Kong Market Announcement Highlights: VGT Launches IPO with CPE Rosewood and Janchor Fund as Cornerstone Investors

Stock News
·
Apr 13

BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPA

Reuters
·
Apr 10

FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization

Stock News
·
Apr 10

Shanghai Fosun Pharma - Unit's Drug Registration Application for Flurbiprofen Axetil Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 10

Fosun Pharma Schedules 28 April Board Meeting to Review Q1 2026 Results

Bulletin Express
·
Apr 10

Fosun Pharmaceutical Names CFO

MT Newswires Live
·
Apr 03

Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug

MT Newswires Live
·
Apr 02

FOSUN PHARMA Subsidiary Receives Clinical Trial Approval for HLX319 Drug

Stock News
·
Apr 01

Fosun Pharmaceutical to Set Up Parallel Fund Structure

MT Newswires Live
·
Apr 01

Fosun Pharma Unit Gets China Nod for Tumor Drug Trial

MT Newswires Live
·
Mar 31

Fosun Pharma Subsidiary Secures NMPA Approval to Launch Phase I Trial of FXB0871 for Advanced Solid Tumors

Bulletin Express
·
Mar 31